Me Report Template
Blencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C. Preterm-associated beheld crime and estimates of retinopathy of prematurity at bounded and all-around levels for 2010. Pediatr Res. 2013;74:35–49.

Retinopathy of Prematurity. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/retinopathy-prematurity (accessed 18 Nov 2020).
Lambert SR, Lyons CJ. Taylor and hoyt’s pediatric ophthalmology and strabismus. 5th ed. England: Elsevier Health Sciences: London; 2016.
Locke JC. Retrolental fibroplasia absolute role of oxygen administering in its etiology. AMA Arch Ophthalmol. 1954;51:73–79.
Szewczyk TS. Retrolental fibroplasia and accompanying ocular diseases; classification, etiology, and prophylaxis. Am J Ophthalmol. 1953;36:1336–61.
Bedrossian RH, Carmichael P, Ritter J. Retinopathy of prematurity (retrolental fibroplasia) and oxygen. I. Analytic study. II. Further observations on the disease. Am J Ophthalmol. 1954;37:78–86.
Shukla A, Sonnie C, Worley S, Sharma A, Howard D, Moore J et al. Comparison of biphasic vs changeless oxygen assimilation targets amid breed with retinopathy of prematurity. JAMA Ophthalmol. 2019. https://doi.org/10.1001/jamaophthalmol.2018.7021.
BOOST II United Kingdom Collaborative Group, BOOST II Australia Collaborative Group, BOOST II New Zealand Collaborative Group, Stenson BJ, Tarnow-Mordi WO, Darlow BA, et al. Oxygen assimilation and outcomes in preterm infants. N. Engl J Med. 2013;368:2094–104.
Gaynon MW, Stevenson DK, Sunshine P, Fleisher BE, Landers MB. Added oxygen may abatement progression of prethreshold ache to beginning retinopathy of prematurity. J Perinatol. 1997;17:434–8.
Werdich XQ, McCollum GW, Rajaratnam VS, Penn JS. Variable oxygen and retinal VEGF levels: alternation with accident and severity of anatomy in a rat archetypal of oxygen-induced retinopathy. Exp Eye Res. 2004;79:623–30.
Sears JE, Pietz J, Sonnie C, Dolcini D, Hoppe G. A change in oxygen supplementation can abatement the accident of retinopathy of prematurity. Ophthalmology. 2009;116:513–8.
Cayabyab R, Arora V, Wertheimer F, Durand M, Ramanathan R. Graded oxygen assimilation targets and retinopathy of prematurity in acutely preterm infants. Pediatr Res. 2016;80:401–6.
Colaizy TT, Longmuir S, Gertsch K, Abrà moff MD, Klein JM. Use of a added oxygen agreement to abolish progression of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2017;58:887–91.
Smith LEH. Pathogenesis of retinopathy of prematurity. Semin Neonatol. 2003;8:469–73.
Hellström A, HÃ¥rd A-L, Engström E, Niklasson A, Andersson E, Smith L, et al. Aboriginal weight accretion predicts retinopathy in preterm infants: new, simple, able access to screening. Pediatrics. 2009;123:e638–45.
Kaempf JW, Kaempf AJ, Wu Y, Stawarz M, Niemeyer J, Grunkemeier G. Hyperglycemia, insulin and slower advance acceleration may access the accident of retinopathy of prematurity. J Perinatol. 2011;31:251–7.
Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, et al. Increased comestible assimilation of omega-3-polyunsaturated blubbery acids reduces dissection retinal angiogenesis. Nat Med. 2007;13:868–73.
Wu C, Löfqvist C, Smith LEH, VanderVeen DK, Hellström A, WINROP Consortium. Importance of aboriginal postnatal weight accretion for accustomed retinal angiogenesis in actual preterm infants: a multicenter abstraction allegory weight acceleration deviations for the anticipation of retinopathy of prematurity. Arch Ophthalmol. 2012;130:992–9.

Gaynon MW. Rethinking STOP-ROP: is it advantageous aggravating to attune boundless VEGF levels in prethreshold ROP eyes by systemic intervention? A analysis of the role of oxygen, ablaze adjustment state, and anemia in prethreshold ROP. Retina. 2006;26:S18–23.
Good WV, Aboriginal Analysis for Retinopathy of Prematurity Cooperative Group. Final after-effects of the aboriginal analysis for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233–48. altercation 248-50
Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, et al. Accident and aboriginal advance of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. 1991;98:1628–40.
Paysse EA, Miller A, Brady McCreery KM, Coats DK. Acquired amaurosis afterwards diode laser photocoagulation for beginning retinopathy of prematurity. Ophthalmology. 2002;109:1662–5.
Vinekar A, Jayadev C, Mangalesh S, Kumar AK, Bauer N, Capone A Jr, et al. Comparing the aftereffect of distinct against assorted affair laser photoblation of collapsed neovascularization in area 1 advancing afterwards retinopathy of prematurity: a -to-be randomized study. Retina. 2015;35:2130–6.
Quinn GE, Dobson V, Davitt BV, Wallace DK, Hardy RJ, Tung B, et al. Progression of amaurosis and aerial amaurosis in the aboriginal analysis for retinopathy of prematurity study: allegation at 4 to 6 years of age. J AAPOS. 2013;17:124–8.
Lambert SR, Capone A Jr, Cingle KA, Drack AV. Cataract and phthisis bulbi afterwards laser photoablation for beginning retinopathy of prematurity. Am J Ophthalmol. 2000;129:585–91.
Chang TC, Tran KD, Cernichiaro-Espinosa LA, Leung EH, Grajewski AL, Hodapp EA, et al. Microcornea and thickened lens in bend cease afterward nonsurgical analysis of retinopathy of prematurity. J Ophthalmol. 2020;2020:7510903.
Trigler L, Weaver RG Jr, O’Neil JW, Barondes MJ, Freedman SF. Case alternation of angle-closure glaucoma afterwards laser analysis for retinopathy of prematurity. J AAPOS. 2005;9:17–21.
Ruth A, Hutchinson AK, Baker Hubbard G. Late brittle drain in patients with regressed retinopathy of prematurity. J AAPOS. 2008;12:181–5.
Kim MJ, Kim S-J, Yu YS. The accident for retinal disengagement associated with hemorrhages pre- and postlaser analysis in retinopathy of prematurity. Retina. 2008;28:1451–7.
Dailey WA, Gryc W, Garg PG, Drenser KA. Frizzled-4 variations associated with retinopathy and intrauterine advance retardation: A abeyant brand for prematurity and retinopathy. Ophthalmology. 2015;122:1917–23.
Spandau U, Larsson E, Holmström G Inadequate laser agglomeration is an important account of analysis abortion in Blazon 1 retinopathy of prematurity. Acta Ophthalmol. 2020. https://doi.org/10.1111/aos.14406.
Hartnett ME. Retinopathy of prematurity: evolving analysis with anti-vascular endothelial advance factor. Am J Ophthalmol. 2020;218:208–13.
Toy BC, Schachar IH, Tan GSW, Moshfeghi DM. Chronic vascular arrest as a augur of bevacizumab analysis abortion in retinopathy of prematurity. Ophthalmology. 2016;123:2166–75.
Huang Q, Zhang Q, Fei P, Xu Y, Lyu J, Ji X, et al. Ranibizumab bang as primary analysis in patients with retinopathy of prematurity: anatomic outcomes and influencing factors. Ophthalmology. 2017;124:1156–64.
Sukgen EA, Koçluk Y. Comparison of analytic outcomes of intravitreal ranibizumab and aflibercept analysis for retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2019;257:49–55.
Bai Y, Nie H, Wei S, Lu X, Ke X, Ouyang X, et al. Efficacy of intravitreal conbercept bang in the analysis of retinopathy of prematurity. Br J Ophthalmol. 2019;103:494–8.
Tolentino M. Systemic and ocular assurance of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2011;56:95–113.
Bakbak B, Ozturk BT, Gonul S, Yilmaz M, Gedik S. Comparison of the aftereffect of unilateral intravitreal bevacizumab and ranibizumab bang on diabetic macular edema of the adolescent eye. J Ocul Pharm Ther. 2013;29:728–32.
Hong YR, Kim YH, Kim SY, Nam GY, Cheon HJ, Lee SJ. Plasma concentrations of vascular endothelial advance agency in retinopathy of prematurity afterwards intravitreal bevacizumab injection. Retina. 2015;35:1772–7.
Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard M-N, et al. Neurodevelopmental outcomes afterward bevacizumab injections for retinopathy of prematurity. Pediatrics. 2016;137:e20153218–e20153218.
Ahmed K, Ali AS, Delwadia N, Greven MA. Neurodevelopmental outcomes afterward intravitreal bevacizumab with laser against laser photocoagulation abandoned for retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retin. 2020;51:220–4.
Tan Q-Q, Christiansen SP, Wang J. Development of refractive absurdity in accouchement advised for retinopathy of prematurity with anti-vascular endothelial advance agency (anti-VEGF) agents: a meta-analysis and analytical review. PLoS ONE. 2019;14:e0225643.
Hamad AE, Moinuddin O, Blair MP, Schechet SA, Shapiro MJ, Quiram PA, et al. Late-onset retinal allegation and complications in basic retinopathy of prematurity. Ophthalmol Retin 2020;4:602–12.
Kusaka S, Shima C, Wada K, Arahori H, Shimojyo H, Sato T, et al. Efficacy of intravitreal bang of bevacizumab for astringent retinopathy of prematurity: a pilot study. Br J Ophthalmol. 2008;92:1450–5.
Lalwani GA, Berrocal AM, Murray TG, Buch M, Cardone S, Hess D, et al. Off-label use of intravitreal bevacizumab (Avastin) for deliver analysis in accelerating beginning retinopathy of prematurity. Retina. 2008;28:S13–8.
Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for date 3 retinopathy of prematurity. N. Engl J Med. 2011;364:603–15.
Wallace DK, Dean TW, Hartnett ME, Kong L, Smith LE, Hubbard GB, et al. A dosing abstraction of bevacizumab for retinopathy of prematurity: Late recurrences and added treatments. Ophthalmology. 2018;125:1961–6.
Yonekawa Y, Thomas BJ, Thanos A, Todorich B, Drenser KA, Trese MT, et al. The acid bend of retinopathy of prematurity care: accretion the boundaries of analysis and treatment. Retina. 2017;37:2208–25.
Patel SN, Klufas MA. Evidence to date: ranibizumab and its abeyant in the analysis of retinopathy of prematurity. Eye Brain. 2019;11:25–35.
Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37:1847–58.
Vural A, Perente İ, Onur İU, EriÅŸ E, Seymen Z, Hergünsel GO, et al. Efficacy of intravitreal aflibercept monotherapy in retinopathy of prematurity evaluated by alternate fluorescence angiography and optical adherence tomography. Int Ophthalmol. 2019;39:2161–9.
Chen Y-T, Liu L, Lai C-C, Chen K-J, Hwang Y-S, Wu W-C Anatomical and anatomic after-effects of intravitreal aflibercept monotherapy for blazon 1 retinopathy of prematurity. Retina 2020. https://doi.org/10.1097/iae.0000000000002754.
Beck KD, Rahman EZ, Ells A, Mireskandari K, Berrocal AM, Armitage Harper C III. SAFER-ROP: Updated Agreement for Anti-VEGF Injections for Retinopathy of Prematurity. https://doi.org/10.3928/23258160-20200702-05.
Wright LM, Harper CA 3rd, Chang EY. Administration of baby and adolescence retinopathies: optimized pediatric pars plana vitrectomy sclerotomy nomogram. Ophthalmol Retin. 2018;2:1227–34.
Cernichiaro-Espinosa LA, Harper CA III, Read SP, Wright LM, Scribbick FW III, Young R, et al. Address of assurance of the use of a abbreviate 32g aggravate for intravitreal anti–vascular endothelial advance agency injections for retinopathy of prematurity. Retina. 2018;38:1251–5.
Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity afterwards bevacizumab injection. Arch Ophthalmol. 2012;130:1000–6.
Yonekawa Y, Wu W-C, Nitulescu CE, Chan RVP, Thanos A, Thomas BJ, et al. Accelerating retinal disengagement in breed with retinopathy of prematurity advised with intravitreal bevacizumab or ranibizumab. Retina. 2018;38:1079–83.
Wood EH, Rao P, Moysidis SN, Dedania VS, Elman MJ, Drenser KA, et al. Adolescent eye anti-VEGF “Crunch” aftereffect in retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retin. 2018;49:e102–e104.
Harper CA 3rd, Wright LM, Young RC, Read SP, Chang EY. Fluorescein angiographic appraisal of borderline retinal vasculature afterwards primary intravitreal ranibizumab for retinopathy of prematurity. Retina. 2019;39:700–5.
Chen TA, Shields RA, Bodnar ZH, Callaway NF, Schachar IH, Moshfeghi DM. A spectrum of corruption afterward intravitreal bevacizumab in retinopathy of prematurity. Am J Ophthalmol. 2019;198:63–69.
Kaiser RS, Trese MT, Williams GA, Cox MS Jr. Adult retinopathy of prematurity: outcomes of rhegmatogenous retinal detachments and retinal tears. Ophthalmology. 2001;108:1647–53.
Park KH, Hwang J-M, Choi MY, Yu YS, Chung H. Retinal disengagement of regressed retinopathy of prematurity in accouchement age-old 2 to 15 years. Retina. 2004;24:368–75.
Drenser KA. Wnt signaling alleyway in retinal vascularization. Eye Brain. 2016;8:141–6.
Wood EH, Drenser KA, Capone A Jr. Analysis and administration of familial exudative vitreoretinopathy: a lifelong, progressive, and generally agee disease. JAMA Ophthalmol. 2019. https://doi.org/10.1001/jamaophthalmol.2019.1484.
Dejana E. The role of wnt signaling in physiological and dissection angiogenesis. Circ Res. 2010;107:943–52.
John VJ, McClintic JI, Hess DJ, Berrocal AM. Retinopathy of prematurity against familial exudative vitreoretinopathy: address on analytic and angiographic findings. Ophthalmic Surg Lasers Imaging Retin. 2016;47:14–19.
Bowe T, Ung C, Campbell JP, Yonekawa Y. Telemedicine for retinopathy of prematurity in 2020. J Vitreoretin Dis. 2019;3:452–8.
Beck K, Young R, Read S, Harper H, Desireddi J, Harper CA. The severity and associated comorbidities of retinopathy of prematurity amid micro-premature breed with bearing weights beneath than 750 grams. J Neonatal Perinat Med. 2019;12:41–45.
Acevedo-Castellón R, RamÃrez-Neria P, GarcÃa-Franco R. Accident of retinopathy of prematurity blazon 1 and blazon 2 in a bounded Hospital of Social Security in the accompaniment of Queretaro, Mexico (2017-2018). BMC Ophthalmol. 2019;19:91.
Senjam S, Chandra P. Retinopathy of prematurity: acclamation the arising accountability in developing countries. J Fam Med Prim Care. 2020;9:2600.
Me Report Template - Me Report Template | Pleasant for you to my personal website, in this particular period We'll explain to you concerning keyword. Now, here is the initial graphic:
Komentar
Posting Komentar